Table IV.
Anti-PD-1 and PD-L1 blockade agents currently* in clinical trials.
| Target/Treatment | Fc Domain |
|---|---|
| PD-1 (blocks interaction between PD-L1 and PD-L2) | |
| Nivolumab, BMS-936558, MDX-1106, ONO-45381 | Human IgG4, stabilizing mutation S228P |
| Pembrolizumab3 | Humanized IgG4, S228P |
| Pidilizumab, CT-01149 | Humanized IgG1 |
| AMP-224 (PD-1 targeting therapy) | PD-L2-Fc fusion protein (blocking) |
| AMP-514, MEDI-0680 | IgG, details unpublished |
| PD-L1 (inhibits binding to PD-1 and CD80) | |
| BMS-9365592 | Human IgG4, S228P |
| MEDI-4736 | Engineered human IgG1 |
| MPDL-3280A57 | Engineered human IgG1 |
| MSB-0010718C | IgG1, details unpublished |
Fc = fragment, crystallizable; Ig = immunoglobulin; PD = programmed cell death protein.
*
Registered on clinicaltrials.gov as of July 7, 2014.